Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.175
Bid: 0.17
Ask: 0.18
Change: -0.01 (-5.41%)
Spread: 0.01 (5.882%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: 7digital Warns Of Need For Capital Raise

Tue, 09th Apr 2019 10:46

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Anglo American, up 0.5%. The miner said its De Beers rough diamond sales in the third sales cycle of 2019 were about 10% higher than the year prior amid "stable" demand. Its third cycle sales in 2019 - as of Tuesday - stood at a provisional USD575 million. This was 9.7% higher than the USD524 million sales reported in the third cycle of 2018 and 16% up on the USD496 million sales reported for the second cycle of 2019.----------FTSE 100 - LOSERS----------Severn Trent, down 2.0%. JPMorgan downgraded the water company to Neutral from Overweight. ----------FTSE 250 - WINNERS----------NewRiver REIT, up 2.5%. The trust declared a fourth-quarter dividend of 5.4 pence per share, which is a 3% increase on the fourth quarterly dividend of 5.25 pence the prior year.----------FTSE 250 - LOSERS----------Pennon Group, down 2.0%. JPMorgan cut the utility stock to Neutral from Overweight. Hays, down 1.5%. Morgan Stanley downgraded the recruiter to Equal Weight from Overweight. Go-Ahead Group, 1.0%. HSBC lowered its rating on the transport operator to Hold from Buy. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Nuformix, up 60%. The pharmaceutical firm said it has signed a cannabinoid therapeutics agreement worth up to GBP51 million with private Canadian company Ebers Tech. The development, licensing and commercialisation agreement contains as much as GBP51 million of upfront, research and development, and milestone payments as well as long-term royalties of 20% of net sales, Nuformix said. Under the agreement, Ebers can use Nuformix's technology platforms to bring therapeutic cannabinoid products to market. Ebers is backed by financial sector leaders with connections to the US cannabinoid market. Nuformix is expecting "a significant upfront payment with further research and development and early-stage milestone payments of up to GBP1 million in 2019. More pre-clinical and milestone payments are likely in 2020 and 2021.Defenx, up 55%. The mobile security software firm said it has signed a software distribution and a software services agreement with majority shareholder BV Tech. The new distribution agreement modifies the terms of a previous deal from 2017. BV Tech - which has a 67% stake in Defenx - now has the sole right to sell Defenx's cyber security products to "bodies within the Italian defence, space, national security or critical infrastructures sector" until the end of 2023. For this, BV Tech will pay EUR1.0 million in three instalments before the end of the first half of 2019 and will also pay a 50% royalty fee to Defenx on any revenue from the sale of its products to clients exceeding EUR5.0 million. BV Tech has also committed, under the distribution agreement, to buy Defenx's products, with a minimal value of EUR1.2 million for a two-year period beginning in January 2019. Prior restrictions have been removed so that BV Tech can now distribute all of Defenx's products on an exclusive basis until the end of 2021. The software services agreement is entirely new. BV Tech will provide software services to Defenx, for which Defenx will pay a maximum of EUR1.2 million. One Media IP Group, up 12%. The digital media content company said annual profit rocketed due to strong streaming demand. The company posted a 63% increase in pretax profit to GBP486,504 for the year ended October 31, 2018, up from GBP297,601 the year before. One Media experienced 17% revenue growth to GBP2.7 million from GBP2.3 million. This was attributed to improved customer demand on streaming platforms, as well as revenue distributions from digital platforms. The company placed some of its music into film and television during its year, with its recording of Chopin's Nocturne Op No 2 in E-Flat Major appearing in Marvel's Daredevil and a new TV series by Jim Carey called 'Kidding'. As at October 31, One Media's cash balance stood at GBP5.6 million versus GBP335,664 the year before. The company added that is "well placed to benefit" from music industry growth and has "a strong pipeline of opportunities".----------OTHER MAIN MARKET AND AIM - LOSERS----------7digital Group, down 63%. The digital music and radio services company warned it requires further funding in the near future to continue trading. Having started a company review, 7digital is taking "a more circumspect" view of its sales pipeline, and it now believes it will need "material" equity or debt funding in the third quarter of 2019. "The board will assess financing options for the company however, it is likely that this would entail significant dilution for shareholders," the company said. As part of the group's new strategy it will no longer be giving a pre-close trading update for 2018, as it decides how to recognise the EUR4.0 million settlement received from MediaMarktSaturn in March. The case related to Media-Saturn subsidiary Juke Entertainment's music service, with Media-Saturn having wanted to end its relationship with 7digital. "The negotiations and ultimate loss of MediaMarktSaturn as a customer prior to John's arrival at the company has diverted management attention and led to disruption within the business during the first quarter as well as having a marked effect on customer sentiment," warned 7digital.Stride Gaming, down 13%. The online gaming operator said its revenue in the first half of its current financial year was lower than expected due to recently implemented regulatory changes. The company expects to report net gaming revenue for the six months to the end of February 5% lower than envisaged due to a disruption from fiscal and regulatory changes in the second half of calendar 2018. However, Stride does now see signs the impact has been largely absorbed and its business model is adjusting accordingly. Looking ahead, the company does not expect to recover the first half revenue shortfall through trading in the second half. Stride expects to report a strong performance from its Stride Together joint venture and is encouraged by further new partnership opportunities.----------

More News
28 Jul 2022 16:14

EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

Read more
28 Jul 2022 15:01

EARNINGS UPDATES: Alliance Trust beats benchmark and ups dividend

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Jun 2022 12:25

IN BRIEF: Nuformix shares rise as progresses with cancer programme

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going."

Read more
27 Jun 2022 21:51

TRADING UPDATES: Anglo-Eastern Plantations sees palm oil prices rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
31 May 2022 12:41

Nuformix Executive Chair Alastair Riddell resigns after one year

(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect.

Read more
30 May 2022 11:54

IN BRIEF: Nuformix shares plunge on inconsistent repeat study results

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says the contract research organisation undertaking the final planned pre-clinical study for its NXP002 treatment had a protocol failure, which has voided the study. Says the organisation repeated the study and recorded results that were inconsistent with the first in vivo study at all time points and also with the oral control. Notes that no positive or negative conclusions could be drawn from this study.

Read more
30 May 2022 11:13

SMALL-CAP WINNERS & LOSERS: Foxtons finds new CEO; S4 revenue surges

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

Read more
28 Mar 2022 19:18

IN BRIEF: Nuformix NXP004 patent application reaches publication phase

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending.

Read more
8 Feb 2022 13:58

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

Read more
8 Feb 2022 10:52

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

Read more
14 Dec 2021 18:01

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

Read more
25 Nov 2021 16:23

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

Read more
12 Nov 2021 12:11

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

Read more
12 Nov 2021 10:54

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

Read more
9 Nov 2021 15:30

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.